Immunotherapy for GU Ca: A primer for urologistsThis article discusses the current status and potential future developments in immunotherapy for genitourinary malignancies with insights from urologic oncology specialists Hyung L. Kim, MD, and Daniel P. Petrylak, MD.
Metastatic RCC: High-dose IL-2 ups overall survivalThe survival benefit associated with high-dose IL-2 in metastatic renal cell carcinoma may be better than previously believed.